Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > It's getting better and better

<< Previous

Bullboard Posts

Next >>

Comment by JimmyJon Feb 16, 2021 8:17am

155 Views

Post# 32571405

RE:RE:RE:It's getting better and better

Sign up for the TMX new alerts. I always get excited when I see those TMX emails in my inbox. Usually means it's going to be a good day. Here's a link to the OTC news

https://money.tmx.com/en/quote/ATE/news/5781590235344280

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market